Valuation
26% of the score, 30% here after data gaps
0median 13
An operating loss over the last year: there are no earnings to price.
MRNAModerna
$62.96+93% 1Y
$62.96
$22.3652 weeks$198.84
RyuScore
Seven criteria, each scored 0 to 100 on a published scale, weighted into one number.
RyuScore 48 out of 100, Average
Average. Moderna scores higher than 47% of the 1,794 companies Ryufin scores.
Carried by return on capital and capital allocation, held back by valuation and return on new capital.
Healthcare median 27 · all companies 50
Return on capital
18% of the score, 20% here after data gaps
100median 34
Over 7 years the business earned 27% a year after tax on the capital it uses.
2%
8%
15%
25%
27%
None at 2% or less, full points from 25%full points
7 years agolatest -65%
Return on new capital
16% of the score, 18% here after data gaps
0median 49
Over 6 years yearly profit fell by 101 cents for every dollar earned. New capital earned -293%, and 34% of profit went back into the business.
-5%
12%
-101%
None at minus 5 cents, full points from 12 centsfull points
Capital allocation
14% of the score, 16% here after data gaps
74median 64
How management spends the money: shares bought back or issued, and whether assets grow faster than the business they serve.
Share countUp 0.4% a year over 5 years: new shares
575%
-3%
0.4%
0 pointsfull points
Assets against salesAssets grew 11% a year, sales 19%
10012%
-2%
-8.4%
0 pointsfull points
Cycle position
Taken out: its 12% is shared by the others
n/ano data
Margins have been too thin to measure a cycle against.
Balance sheet
8% of the score, 9% here after data gaps
100median 50
What the debt weighs against the profit that has to carry it.
Net debt to EBITDAMore cash than debt
100Interest coverNo interest to pay
100Earnings quality
6% of the score, 7% here after data gaps
98median 90
Whether the reported profit arrives as cash, and whether the accounts show the usual signs of stretching.
AccrualsCash ran ahead of profit by 7.2% of assets
968%
0%
-8%
-7.2%
0 pointsfull points
Beneish M-score-3.48
100-1.50
-1.78
-2.22
-3.00
-3.48
0 pointsfull points
How the RyuScore works
Each criterion earns 0 to 100 points on the scale drawn under it, and the RyuScore is their average weighted 26, 18, 16, 14, 12, 8 and 6. Scales bend in the company's favour between their ends, so an ordinary figure is never already near zero. For MRNA, cycle position could not be measured from the filings, so it is taken out and the remaining weights scale up.
Built from the company's annual and quarterly filings with the SEC and today's share price. Banks, insurers and property trusts are not scored: their debt is their raw material, so these yardsticks mean something else there. Figures as of 2026-06-30, latest annual report FY2025.
Biotechnology
The closest names by size in the same industry